Vor Bio, a clinical-stage biotech company, granted stock options for 61,050 shares and RSUs for 12,900 shares to 10 newly hired employees as inducements to employment. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are part of the company's 2023 Inducement Plan. The stock options have a 10-year term with an exercise price of $14.57, vesting over four years, while the RSUs also vest over four years. This move aims to attract and retain talent as Vor Bio advances its autoimmune disease treatments, including its lead drug telitacicept in late-stage clinical trials.
Ether has surged about 11% over the past week, outperforming other major cryptocurrencies like Bitcoin, which rose 4%. This rise is driven by $96 million inflows into U.S. spot ether ETFs, mainly BlackRock’s low-fee funds, while Grayscale’s higher-fe...
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
